Epameinondas Dogeas1, Georgios Karagkounis1, Christopher M Heaphy2, Kenzo Hirose1, Timothy M Pawlik1, Christopher L Wolfgang1, Alan Meeker2, Ralph H Hruban2, John L Cameron1, Michael A Choti3. 1. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD. 2. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD. 3. Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: michael.choti@utsouthwestern.edu.
Abstract
BACKGROUND: The determination of the primary tumor origin in patients with neuroendocrine tumor liver metastases (NELM) can pose a considerable management challenge. Recent studies have shown that the alternative lengthening of telomeres (ALT) is prevalent in some human tumors, including pancreatic neuroendocrine tumors (PanNET), and can be useful in predicting tumor biology. In this study, we aimed to evaluate the use of ALT as a biomarker in patients with NELM, in particular to predict the site of origin of metastases. METHODS: Tissue microarrays (TMAs) were constructed using tumor tissue from NELM patients undergoing liver resection between 1998 and 2010. These included 43 PanNET and 47 gastrointestinal carcinoid tumors. The TMAs were tested for ALT using telomere-specific fluorescent in situ hybridization. The association between ALT positivity and clinicopathologic features and long-term outcomes was investigated. RESULTS: Alternative lengthening of telomeres was positive (ALT+) in 26 (29%) of the 90 tumors included in the TMAs. Pancreatic neuroendocrine tumors were ALT+ in 56% of patients, compared with only 4% ALT+ among gastrointestinal carcinoid tumors (p < 0.001). The specificity of ALT for detecting pancreatic origin was 96% and the positive predictive value was 92%, and sensitivity was 56% and the negative predictive value was 70%. Additionally, ALT was associated with the pattern of metastatic disease: ALT+ NELM were more likely to have oligometastases (p = 0.001) and less likely to be bilateral in distribution (p = 0.05) than were ALT tumors. In addition, ALT+ was associated with improved prognosis in the PanNET patient population. CONCLUSIONS: Alternative lengthening of telomeres was found to be a useful biomarker in patients with NELM. This marker can be helpful in guiding therapy by identifying the site of origin in patients in whom the primary site is unknown.
BACKGROUND: The determination of the primary tumor origin in patients with neuroendocrine tumor liver metastases (NELM) can pose a considerable management challenge. Recent studies have shown that the alternative lengthening of telomeres (ALT) is prevalent in some humantumors, including pancreatic neuroendocrine tumors (PanNET), and can be useful in predicting tumor biology. In this study, we aimed to evaluate the use of ALT as a biomarker in patients with NELM, in particular to predict the site of origin of metastases. METHODS: Tissue microarrays (TMAs) were constructed using tumor tissue from NELM patients undergoing liver resection between 1998 and 2010. These included 43 PanNET and 47 gastrointestinal carcinoid tumors. The TMAs were tested for ALT using telomere-specific fluorescent in situ hybridization. The association between ALT positivity and clinicopathologic features and long-term outcomes was investigated. RESULTS: Alternative lengthening of telomeres was positive (ALT+) in 26 (29%) of the 90 tumors included in the TMAs. Pancreatic neuroendocrine tumors were ALT+ in 56% of patients, compared with only 4% ALT+ among gastrointestinal carcinoid tumors (p < 0.001). The specificity of ALT for detecting pancreatic origin was 96% and the positive predictive value was 92%, and sensitivity was 56% and the negative predictive value was 70%. Additionally, ALT was associated with the pattern of metastatic disease: ALT+ NELM were more likely to have oligometastases (p = 0.001) and less likely to be bilateral in distribution (p = 0.05) than were ALT tumors. In addition, ALT+ was associated with improved prognosis in the PanNET patient population. CONCLUSIONS: Alternative lengthening of telomeres was found to be a useful biomarker in patients with NELM. This marker can be helpful in guiding therapy by identifying the site of origin in patients in whom the primary site is unknown.
Authors: Sam C Wang; Justin R Parekh; Marlene B Zuraek; Alan P Venook; Emily K Bergsland; Robert S Warren; Eric K Nakakura Journal: Arch Surg Date: 2010-03
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Emma Z Du; P Goldstraw; Jo Zacharias; Olivier Tiffet; Paul J Craig; Andrew G Nicholson; Noel Weidner; Eunhee S Yi Journal: Hum Pathol Date: 2004-07 Impact factor: 3.466
Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544
Authors: Anja M Schmitt; Florian Riniker; Martin Anlauf; Sonja Schmid; Alex Soltermann; Holger Moch; Philipp U Heitz; Günther Klöppel; Paul Komminoth; Aurel Perren Journal: Am J Surg Pathol Date: 2008-03 Impact factor: 6.394
Authors: Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong Journal: Clin Cancer Res Date: 2016-09-23 Impact factor: 12.531
Authors: Jeong-Hwa Kwon; Hyoung Jung Kim; Do Hyun Park; Young-Joo Lee; Christopher M Heaphy; Günter Klöppel; Ralph H Hruban; Seung-Mo Hong Journal: Virchows Arch Date: 2018-07-12 Impact factor: 4.064
Authors: Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre Journal: Genes (Basel) Date: 2018-05-03 Impact factor: 4.096